Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 10/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249479 | 0.87 | PTGDR2 (0.71) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1251777 | 0.87 | PTGDR2 (0.55) | PTGDR2AKR1B1CYP2C9NPC1LOXL2 | |
| SCHEMBL3575633 | 0.85 | PTGDR2 (0.53) | PTGDR2AKR1B1CYP2C9NPC1LOXL2 | |
| SCHEMBL2550525 | 0.84 | PTGDR2 (0.52) | PTGDR2AKR1B1CYP2C9NPC1LOXL2 | |
| SCHEMBL1251115 | 0.84 | PTGDR2 (0.52) | PTGDR2AKR1B1CYP2C9NPC1LOXL2 | |
| SCHEMBL1406010 | 0.84 | PTGDR2 (0.73) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1251069 | 0.83 | PTGDR2 (0.71) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1251108 | 0.83 | PTGDR2 (0.57) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1251057 | 0.80 | PTGDR2 (0.48) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1251755 | 0.79 | PTGDR2 (0.75) | PTGDR2AKR1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2025670-A1 | 3-(Phenyl or quinolyl)thio-1H-indole-1-acetic acid derivatives as modulators of CRTh2 receptor activity | AstraZeneca AB (SE) | 2009-02-18 | — | — | EP | disclosed |